Ask AI

Decoding Discoveries in Hematologic Malignancies—Decera Clinical Education's Independent Highlights of the 2026 ASCO and EHA Conferences

Review practice-changing data on the treatment of lymphoma and leukemia from the 2026 ASCO and EHA annual meetings through Capsule Summaries, 2 ClinicalThought commentaries, and a certified expert-authored text module.

For coverage of gastrointestinal, lung, and breast cancers at ASCO 2026, click here.

Share

Program Content

Activities

frontMIND
frontMIND: Phase III Trial of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP for Newly Diagnosed DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2026

BRUIN CLL 313 314 Pooled Analysis
BRUIN CLL-313 and BRUIN CLL-314: A Pooled Analysis of Pirtobrutinib in Previously Untreated CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

CLL14
CLL14: Final Analysis of Phase III Study of First-line Venetoclax + Obinutuzumab for CLL 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

BRUIN CLL 322
BRUIN CLL-322: Phase III Trial of Fixed-Duration Pirtobrutinib + Venetoclax/Rituximab vs Venetoclax/Rituximab in Previously Treated CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2026

SOUNDTRACK F1
SOUNDTRACK-F1: Initial Safety and Efficacy From a Phase III Trial of First-line Surovatamig + Rituximab for Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

Sonrotoclax Plus Zanubrutinib in TN CLL
Sonrotoclax + Zanubrutinib in Treatment-Naive CLL/SLL: A Phase I Study
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

AJX 101
AJX-101: Phase I Study of AJ1-11095, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis After Prior Type I JAK2 Inhibitor Treatment
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

ASC4FIRST Wk 144 Update
ASC4FIRST: Wk 144 Update of Asciminib vs Investigator-Selected TKI in Newly Diagnosed CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2026

EPO-PRETAR
EPO-PRETAR: Final Results With Early vs Delayed Erythropoiesis-Stimulating Agent Initiation in Nontransfusion-Dependent Patients With Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2026

OPTI-AML
OPTI-AML: Phase II Trial of 28-Day vs 14-Day Venetoclax and Azacitidine for 2 Cycles in Patients Aged ≥60 Years with Newly Diagnosed Genomically Agnostic AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2026

SENTRY
SENTRY: Phase III Study of Selinexor + Ruxolitinib in Patients With JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2026

KOMET 007
KOMET-007: Long-term Results From the Phase I Trial of Ziftomenib Plus 7 + 3 Intensive Induction Therapy in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 06, 2026

CaDAnCe 101 CLL
CaDAnCe-101: Update From a Phase I Study of BTK Degrader Tacabrutideg (BGB-16673) in R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2026

MAXILUS
MAXILUS: Primary Analysis of the Phase III Trial of Luspatercept Initiation at Maximum-Approved Dose in Patients With Lower-Risk MDS Requiring Transfusions
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 08, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation